CONTEXT: Disease Modifying Anti-Rheumatic Drugs (DMARDs) are aimed to interfere with rheumatoid arthritis (RA) progression and reduce the joint damage; however, not all patients respond alike. Killer-cell immunoglobulin-like receptors (KIR) and their ligands, human leucocyte antigen class I (HLA-I), have been associated with RA pathology; therefore, KIR and HLA genes may influence the treatment response. MATERIALS AND METHODS: We evaluated the association of KIR genotype and their ligands HLA-C genes with the response to DMARDs in RA patients. We included 69 patients diagnosed with RA and 82 healthy individuals as the reference group. KIR and HLA-C genotyping was performed using SSP-PCR. RA patients were assessed at baseline and under treatment at 6 and 12 months; subsequently classified as responders and non-responders in each time period. We evaluated the association between DMARD response and genes using statistical analysis by using Fisher exact test with Bonferroni correction; results were regarded as statistically significant at p < 0.05. RESULTS: Significant difference was observed in gene frequencies of patients and the reference group, KIR2DL2 was associated with RA (p = 0.031, OR = 2.119). We also observed an association between KIR2DS2 and the response to methotrexate (MTX), moreover, the combination KIR2DL2+/KIR2DS2+ was more frequent in responders to MTX (p = 0.043). DISCUSSION AND CONCLUSIONS: In our results, responders and non-responders to DMARDs showed KIR2DS2 and KIR2DL2 different gene frequencies, therefore, these genes could be used as response predictors to DMARDs treatment. Thus, these genes were also associated with disease severity, as well as the treatment response possibly by the immunoregulatory function of NK cells.
CONTEXT: Disease Modifying Anti-Rheumatic Drugs (DMARDs) are aimed to interfere with rheumatoid arthritis (RA) progression and reduce the joint damage; however, not all patients respond alike. Killer-cell immunoglobulin-like receptors (KIR) and their ligands, human leucocyte antigen class I (HLA-I), have been associated with RA pathology; therefore, KIR and HLA genes may influence the treatment response. MATERIALS AND METHODS: We evaluated the association of KIR genotype and their ligands HLA-C genes with the response to DMARDs in RApatients. We included 69 patients diagnosed with RA and 82 healthy individuals as the reference group. KIR and HLA-C genotyping was performed using SSP-PCR. RApatients were assessed at baseline and under treatment at 6 and 12 months; subsequently classified as responders and non-responders in each time period. We evaluated the association between DMARD response and genes using statistical analysis by using Fisher exact test with Bonferroni correction; results were regarded as statistically significant at p < 0.05. RESULTS: Significant difference was observed in gene frequencies of patients and the reference group, KIR2DL2 was associated with RA (p = 0.031, OR = 2.119). We also observed an association between KIR2DS2 and the response to methotrexate (MTX), moreover, the combination KIR2DL2+/KIR2DS2+ was more frequent in responders to MTX (p = 0.043). DISCUSSION AND CONCLUSIONS: In our results, responders and non-responders to DMARDs showed KIR2DS2 and KIR2DL2 different gene frequencies, therefore, these genes could be used as response predictors to DMARDs treatment. Thus, these genes were also associated with disease severity, as well as the treatment response possibly by the immunoregulatory function of NK cells.
Entities:
Keywords:
Autoimmunity; DMARDs; KIR genes; pharmacogenetics; treatment response
Authors: C M Mariaselvam; R Tamouza; R Krishnamoorthy; D Charron; D P Misra; V K Jain; V S Negi Journal: Clin Exp Immunol Date: 2016-12-18 Impact factor: 4.330
Authors: Amy K Erbe; Wei Wang; Lakeesha Carmichael; KyungMann Kim; Eneida A Mendonça; Yiqiang Song; Dustin Hess; Patrick K Reville; Wendy B London; Arlene Naranjo; Jacquelyn A Hank; Mitchell B Diccianni; Ralph A Reisfeld; Stephen D Gillies; Katherine K Matthay; Susan L Cohn; Michael D Hogarty; John M Maris; Julie R Park; M Fevzi Ozkaynak; Andrew L Gilman; Alice L Yu; Paul M Sondel Journal: Clin Cancer Res Date: 2017-10-02 Impact factor: 12.531
Authors: Amy K Erbe; Wei Wang; Lakeesha Carmichael; Anna Hoefges; Bartosz Grzywacz; Patrick K Reville; Erik A Ranheim; Jacquelyn A Hank; KyungMann Kim; Songwon Seo; Eneida A Mendonca; Yiqiang Song; Vaishalee P Kenkre; Fangxin Hong; Randy D Gascoyne; Elisabeth Paietta; Sandra J Horning; Jeffrey S Miller; Brad Kahl; Paul M Sondel Journal: J Immunother Cancer Date: 2019-03-12 Impact factor: 13.751
Authors: Andrea Carolina Machado-Sulbaran; María Guadalupe Ramírez-Dueñas; José Eduardo Navarro-Zarza; José Francisco Muñoz-Valle; Francisco Mendoza-Carrera; Christian Johana Baños-Hernández; Isela Parra-Rojas; Margarita Montoya-Buelna; Pedro Ernesto Sánchez-Hernández Journal: J Immunol Res Date: 2019-01-06 Impact factor: 4.818